Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Influenza virus vaccine (NasoVAX) (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions; Proof of concept
- Sponsors Altimmune
- 21 Sep 2017 Status changed from not yet recruiting to recruiting.
- 20 Sep 2017 According to an Altimmune media release, the company have been cleared by the FDA to initiate this trial.
- 21 Aug 2017 According to an Altimmune media release, Company has submitted an Investigational New Drug (IND) application to the U.S Food and Drug Administration (FDA) for this phase II trial.